Moderna Revenue 2017-2021 | MRNA
For a detailed definition, formula and example for Revenue, check out our new background page here.
Moderna annual/quarterly revenue history and growth rate from 2017 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Moderna revenue for the quarter ending September 30, 2021 was $4.969B, a 3064.97% increase year-over-year.
- Moderna revenue for the twelve months ending September 30, 2021 was $11.831B, a 4708.44% increase year-over-year.
- Moderna annual revenue for 2020 was $0.803B, a 1234.34% increase from 2019.
- Moderna annual revenue for 2019 was $0.06B, a 55.42% decline from 2018.
- Moderna annual revenue for 2018 was $0.135B, a 34.38% decline from 2017.
Moderna Annual Revenue
(Millions of US $) |
| 2020 |
$803 |
| 2019 |
$60 |
| 2018 |
$135 |
| 2017 |
$206 |
| 2016 |
$108 |
Moderna Quarterly Revenue
(Millions of US $) |
| 2021-09-30 |
$4,969 |
| 2021-06-30 |
$4,354 |
| 2021-03-31 |
$1,937 |
| 2020-12-31 |
$571 |
| 2020-09-30 |
$157 |
| 2020-06-30 |
$67 |
| 2020-03-31 |
$8 |
| 2019-12-31 |
$14 |
| 2019-09-30 |
$17 |
| 2019-06-30 |
$13 |
| 2019-03-31 |
$16 |
| 2018-12-31 |
$35 |
| 2018-09-30 |
$42 |
| 2018-06-30 |
$29 |
| 2018-03-31 |
$29 |
| 2017-12-31 |
|
| 2016-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$70.577B |
$0.803B |
|
Moderna Inc. is a clinical stage biotechnology company pioneering messenger RNA therapeutics and vaccines for patients. The company's product pipeline which is in clinical stage consists of mRNA-1647 for Cytomegalovirus Infectious Disease, mRNA-4157 for Solid tumors, mRNA-2416 for lymphoma and mRNA- 2752 for Relapsed/Refractory solid tumors malignancies. Moderna Inc. is based in Cambridge, United States.
|
